Peter Kabos - Concepedia

Author

Peter Kabos

Also Known As

Espinosa, Joaquin M., K Peter, K. Peter, Kabos Peter, Kabos, Peter, Kaitlyn B. Hill, Kline, Enos, P Kabos, P. Kabos, Peter Kabos

336

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Anschutz Medical Campus University of Colorado Cancer Center The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

Peter Kabos is an author at University of Colorado Denver specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	28	1.1K
2	Cell Biology	10	10	522
3	Health Sciences	4	4	158
4	Engineering	1	1	25
5	Biochemistry	1	1	12

Peter Kabos

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression Ori Maller, Allison P. Drain, Alexander Barrett, Nature Materials	2020	291
ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases Priya Kumthekar, Shou‐Ching Tang, Andrew Brenner, Clinical Cancer Research	2020	230
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen Heather M. Brechbuhl, Jessica Finlay-Schultz, Tomomi M. Yamamoto, Clinical Cancer Research	2016	227
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Clinical Cancer Research	2020	189
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures Peter Kabos, Jessica Finlay-Schultz, Chunling Li, Breast Cancer Research and Treatment Breast OncologyHormone Receptor HeterogeneityHormonal ReceptorGynecologyBreast Cancer	2012	139
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo, Clinical Cancer Research	2017	139
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts Kathryn B. Horwitz, Wendy W. Dye, J. Chuck Harrell, Proceedings of the National Academy of Sciences	2008	131
Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers Peter Kabos, James M. Haughian, Xinshuo Wang, Breast Cancer Research and Treatment Positive CellsBreast OncologyMedicineTherapy Resistant SubpopulationCytokeratin 5	2010	112
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Journal of Clinical Oncology	2021	106
Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways Ritsuko Iwanaga, Chuan Wang, Douglas S. Micalizzi, Breast Cancer Research	2012	90

Page 1